TCGA-E7-A97P-01A-11R-A38B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.35611038
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.740
- INTERFERON_GAMMA_RESPONSE+0.650
- ALLOGRAFT_REJECTION+0.580
- IL6_JAK_STAT3_SIGNALING+0.510
- INFLAMMATORY_RESPONSE+0.490
- TGF_BETA_SIGNALING+0.490
- PROTEIN_SECRETION+0.480
- COMPLEMENT+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- TNFA_SIGNALING_VIA_NFKB+0.460
Top 10 suppressed
- SPERMATOGENESIS-0.210
- KRAS_SIGNALING_DN-0.180
- PANCREAS_BETA_CELLS-0.150
- BILE_ACID_METABOLISM-0.080
- MYOGENESIS+0.020
- XENOBIOTIC_METABOLISM+0.040
- ADIPOGENESIS+0.050
- FATTY_ACID_METABOLISM+0.100
- HEME_METABOLISM+0.100
- UV_RESPONSE_UP+0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934750 | — | — | 0.956 |
| 2 | DB34442C-1882-495A-A2F0-2427116A1FAF | — | — | 0.953 |
| 3 | 2D0A1BA3-EC1D-4B4F-A383-9353C0F4BE85 | — | — | 0.951 |
| 4 | E9FC1686-028B-476C-B51B-4956213D874B | — | — | 0.950 |
| 5 | C13F6AB6-41C0-4F51-A240-BA4F4410B68E | — | — | 0.950 |
| 6 | 795FBB8C-0E74-477F-AA27-1CE97A4E90B9 | — | — | 0.948 |
| 7 | C6A60028-2402-4048-90DF-F2B3712FB530 | — | — | 0.946 |
| 8 | SRR934782 | — | — | 0.946 |
| 9 | A678E1E5-E02D-49A1-BB2B-C91A60E6382E | — | — | 0.942 |
| 10 | SRR934921 | — | — | 0.941 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 46 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.740 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.650 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.580 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.510 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.490 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.490 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.480 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.470 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.460 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| COAGULATION | 0.440 | Binimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.430 | Inavolisib | — uncovered |
| APOPTOSIS | 0.400 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.380 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.370 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.370 | Idelalisib | — uncovered |